1stOncology™: Cancer Intelligence Service – Page 14383 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

OncoCyte Corporation to Present at the Piper Jaffray 30th Annual Health Care Conference

On November 19, 2018 OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, reported that the Company will provide a corporate overview at the Piper Jaffray 30th Annual Health Care Conference, being held November 27-29, 2018 at the Lotte New York Palace Hotel in New York, NY (Press release, Oncocyte, NOV 19, 2018, View Source [SID1234531492]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

OncoCyte Corporation Presentation Details:

Date: Thursday, November 29
Time: 10:00am Eastern Time
Location: Lotte New York Palace Hotel
Webcast: View Source;tp_key=48b258fde4

Eagle Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

On November 19, 2018 Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, NOV 19, 2018, View Source [SID1234531489]):

Date: Wednesday, November 28, 2018
Time: 9:30 a.m. Eastern Standard Time
Location: Lotte New York Palace, New York
Webcast:

View Source;tp_key=451ca78d8f

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

Myriad Announces $50 Million Accelerated Share Repurchase Program

On Npvember 19, 2018 Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, reported that the company has entered into an accelerated share repurchase ("ASR") agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock (Press release, Myriad Genetics, NOV 19, 2018, View Source [SID1234531482]). Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the company’s board of directors.

"We remain highly confident in the future growth prospects for the company and believe repurchasing shares at current levels will generate a very attractive return on invested capital," said R. Bryan Riggsbee, chief financial officer, Myriad Genetics. "Given our strong balance sheet, we continue to be flexible in our capital deployment, and while we prioritize strategic acquisitions, we will opportunistically consider share repurchases if stock valuation is inconsistent with long-term fundamentals."

Under the ASR program, Myriad will pay an aggregate of approximately $50 million to Bank of America, N.A. to repurchase a number of shares that will be based on a discount to the volume-weighted average share price of its common stock over the course of a valuation period.

Bausch Health Announces Participation In Upcoming Investor Conferences

On November 19, 2018 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that the company will participate in three upcoming investor conferences (Press release, Valeant, NOV 19, 2018, View Source [SID1234531479]).

Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 30th Annual Piper Jaffray Healthcare Conference in New York on Nov. 27, 2018 at 10:30 a.m. ET.

Paul S. Herendeen, executive vice president and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Evercore ISI HealthconX Conference on Nov. 28, 2018 in Boston at 3:30 p.m. ET.

Paul S. Herendeen, executive vice president and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the 2018 Citi Global Healthcare Conference on Dec. 5, 2018 in New York at 8:45 a.m. ET.

Live webcasts and audio archives of the events will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: View Source

RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp.

On November 19, 2018 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, reported that its corporate name change from RXi Pharmaceuticals Corporation to Phio Pharmaceuticals Corp. became effective at 12:01 a.m. Eastern Time today, November 19, 2018 (Press release, RXi Pharmaceuticals, NOV 19, 2018, View Source [SID1234531476]). In connection with the name change, the Company’s shares of common stock will trade under a new ticker symbol, "PHIO," and a new CUSIP number, 71880W204, at the market open today. In addition, the Company’s warrants that are currently trading on the Nasdaq Capital Market will begin trading under the new ticker symbol, "PHIOW," and new CUSIP number, 71880W105. Concurrently, the Company is launching a new website, www.phiopharma.com.

Said Dr. Gerrit Dispersyn, President & COO of Phio Pharmaceuticals, "The name change from RXi Pharmaceuticals to Phio Pharmaceuticals reflects the completion of our Company’s transition from a platform company to one that is fully committed to develop groundbreaking immuno-oncology therapeutics based on our self-delivering RNAi platform."